Latest / Glaucoma, Vision & Longevity: Supplements & Science / A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In

Transcript

A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: A new glaucoma procedure uses donor tissue to keep the eye's drainage canal open.
• 0:05
  SPEAKER_00: First human results are in.
• 0:07
  SPEAKER_00: Short answer: the first results are encouraging, but they do not yet show that donor tissue makes canalplasty more durable.
• 0:14
  SPEAKER_00: The reported 52i study has no published full paper, no control group, and only six months of follow-up.
• 0:22
  SPEAKER_00: Because the procedure was combined with cataract surgery, some, and possibly a substantial part, of the pressure drop may have come from cataract removal rather than the allograft.
• 0:32
  SPEAKER_00: The idea is plausible.
• 0:34
  SPEAKER_00: Open Schlem's canal, then support it with donor tissue.
• 0:37
  SPEAKER_00: But the key claim that this support prevents clinically important canal recoil and improves lasting pressure control still needs a randomized comparison.
• 0:47
  SPEAKER_00: Evidence reviewed through October 16, 2026.
• 0:51
  SPEAKER_00: What the first 52 eye results show, on October 8, 2026, Eantrec announced preliminary six-month results from a first-in-human, single-center observational study of bio-reinforced canilloplasty combined with cataract surgery.
• 1:06
  SPEAKER_00: The company reported outcomes for 52 treated eyes.
• 1:10
  SPEAKER_00: The full study report was not published with the announcement.
• 1:13
  SPEAKER_00: The data were described as on file and subject to further analysis.
• 1:17
  SPEAKER_00: Eantrec's October 8th announcement, Ophthalmology Managements Report.
• 1:22
  SPEAKER_00: For the full table, please open this article on VisualFieldtest.com.
• 1:27
  SPEAKER_00: The 14.1 figure is calculated, not separately published, 22.4 times 1-0.372 equals 14.07.
• 1:37
  SPEAKER_00: Because the baseline and percentage are rounded, the exact study mean might differ slightly.
• 1:41
  SPEAKER_00: The medication calculation is also approximate.
• 1:44
  SPEAKER_00: A 49.1% reduction from 1.2 medications implies a reduction of about 0.59, leaving an average of about 0.61.
• 1:52
  SPEAKER_00: These are the figures in the company announcement, not independently audited results.
• 1:58
  SPEAKER_00: No serious adverse events does not mean there were no minor events, and a group of 52 eyes followed for six months cannot rule out uncommon complications or late problems.
• 2:09
  SPEAKER_00: Important study details are not yet public.
• 2:12
  SPEAKER_00: The announcement does not provide enough information to establish several facts requested for a proper clinical assessment.
• 2:19
  SPEAKER_00: Glaucoma severity and subtype, not reported for the 52I cohort.
• 2:24
  SPEAKER_00: Patient age, not reported.
• 2:27
  SPEAKER_00: Previous selective laser trabeculoplasty or minimally invasive glaucoma surgery, not reported.
• 2:33
  SPEAKER_00: Detailed inclusion criteria, not reported.
• 2:36
  SPEAKER_00: Medication washout before baseline pressure measurement, not reported.
• 2:40
  SPEAKER_00: This matters.
• 2:40
  SPEAKER_00: A pressure measured after stopping drops is not directly comparable with one measured while patients are taking them.
• 2:46
  SPEAKER_00: Cataract surgery.
• 2:48
  SPEAKER_00: The study is described as bio-reinforced canalplasty performed with cataract surgery.
• 2:53
  SPEAKER_00: That implies the reported 52 eyes had combined surgery, but the press release does not provide a patient-by-patient study table.
• 3:01
  SPEAKER_00: Exact surgical steps, the type of dilation, how much of the canal was treated, and the precise graft placement steps are not reported.
• 3:09
  SPEAKER_00: Allographed length and exact placement extent, not reported for allo span.
• 3:14
  SPEAKER_00: Postoperative eyedrop regimen, not reported.
• 3:17
  SPEAKER_00: A separate, ongoing study called Boost is registered as an observational study of bioreinforced caniloplasty.
• 3:25
  SPEAKER_00: Its registry describes placing minimally manipulated homologous use scleral allograft tissue in the wall region of Schlem's canal after caniloplasty.
• 3:34
  SPEAKER_00: It targets 300 participants and plans two years of follow-up.
• 3:38
  SPEAKER_00: It is not a randomized comparison of graft versus no graft.
• 3:42
  SPEAKER_00: Boost's eligibility rules should not be assumed to describe the earlier 52 eye study, Boost study record, what bioreinforced caniloplasty means.
• 3:52
  SPEAKER_00: The eye continuously produces clear fluid called aqueous humor.
• 3:57
  SPEAKER_00: It normally drains through the trabecular meshwork into Schlem's canal and then through collector channels toward the veins around the eye.
• 4:05
  SPEAKER_00: In open-angle glaucoma, pressure can rise when this drainage system does not carry fluid away efficiently.
• 4:11
  SPEAKER_00: Conventional caniloplasty.
• 4:13
  SPEAKER_00: In conventional caniloplasty, a surgeon uses an instrument to enter and dilate Schlem's canal, commonly by delivering a viscoelastic fluid.
• 4:22
  SPEAKER_00: Some versions also place a tensioning suture around the canal.
• 4:25
  SPEAKER_00: Other, newer AB internal procedures do not.
• 4:29
  SPEAKER_00: The goal is to stretch the canal and improve flow through the eye's existing drainage route.
• 4:34
  SPEAKER_00: The proposed alospan approach, bioreinforced canaloplasty, adds another step.
• 4:39
  SPEAKER_00: After dilating the canal, the surgeon places homologous donor scleral tissue in the canal wall region to provide structural support.
• 4:47
  SPEAKER_00: Public descriptions also characterize the platform as nitinol-guided and trabecular meshwork sparing, but the detailed steps used in the 52i study have not been published.
• 4:57
  SPEAKER_00: Boost study record, Eantrex Alaspan Introduction.
• 5:01
  SPEAKER_00: The concept is therefore conventional approach, dilate the canal, hope the improved opening and flow persist.
• 5:08
  SPEAKER_00: Biore-reinforced approach, dilate the canal, then add a biological scaffold intended to support its structure.
• 5:16
  SPEAKER_00: The word reinforce describes the intended mechanical role.
• 5:19
  SPEAKER_00: It does not yet establish that the canal stays wider, that collector channel flow improves, or that pressure control lasts longer.
• 5:27
  SPEAKER_00: Does Schlem's canal actually collapse or recoil after canaloplasty?
• 5:31
  SPEAKER_00: Canal narrowing is a real feature of eye anatomy.
• 5:35
  SPEAKER_00: But current evidence does not establish that post-surgical recoil is a major cause of conventional canaloplasty losing effectiveness.
• 5:43
  SPEAKER_00: What imaging and tissue studies show anterior segment optical coherence tomography studies have found that Schlem's canal can be larger after canaloplasty.
• 5:53
  SPEAKER_00: One study documented increased canal dimensions during the first few months after surgery.
• 5:59
  SPEAKER_00: Another examined canal and trabecular meshwork changes one year after combined cataract surgery and canaloplasty.
• 6:06
  SPEAKER_00: Those studies support the idea that surgery changes the canal's anatomy.
• 6:10
  SPEAKER_00: They do not show that later pressure rises are caused by canal recoil or that a graph prevents such rises.
• 6:17
  SPEAKER_00: Three-month imaging study, one year phacocanaloplasty imaging study.
• 6:22
  SPEAKER_00: Laboratory and histological work also shows that the trabecular meshwork can bow toward and narrow the canal as pressure changes.
• 6:29
  SPEAKER_00: But Schlem's canal is not simply an empty pipe.
• 6:32
  SPEAKER_00: Its walls, internal supports, collector channel openings, and surrounding tissues all respond to pressure.
• 6:39
  SPEAKER_00: Histopathological review of trabecular surgery, study of Schlem's canal and collector channel anatomy.
• 6:46
  SPEAKER_00: Conventional canaloplasty can last for years without an allograft.
• 6:50
  SPEAKER_00: Longer-term clinical results show that conventional caniloplasty can retain meaningful effects, although the evidence is mostly non-randomized and outcomes vary.
• 7:00
  SPEAKER_00: In a multi-center three-year study, the overall mean pressure was 15.2, while eyes having combined cataract surgery and caniloplasty averaged 13.6.
• 7:11
  SPEAKER_00: In a separate 10-year observational study, mean pressure at 10 years was 15.9 after caniloplasty alone and 14.2 after combined cataract surgery and caniloplasty.
• 7:22
  SPEAKER_00: Medication use rose over time in some groups, suggesting that pressure lowering and medication reduction are not the same thing.
• 7:30
  SPEAKER_00: 3-year caniloplasty results, 10-year caniloplasty results.
• 7:34
  SPEAKER_00: These studies do not prove that canal anatomy never changes after surgery.
• 7:39
  SPEAKER_00: They do show that a donor scaffold is not already known to be necessary for long-term canalplasty benefit.
• 7:46
  SPEAKER_00: A key missing link is evidence that patients whose canal later narrows are the same patients whose pressure control fails.
• 7:53
  SPEAKER_00: A larger canal may not solve all drainage problems.
• 7:57
  SPEAKER_00: Even with a wider canal, fluid must still pass through the collector channels and other downstream tissues.
• 8:03
  SPEAKER_00: Research suggests a substantial share of resistance can lie beyond Schlem's canal, in the collector channel and venous pathways.
• 8:11
  SPEAKER_00: So keeping the canal open could help, but it cannot necessarily fix blocked or poorly functioning downstream drainage.
• 8:19
  SPEAKER_00: Review of Schlem's canal procedures and outflow resistance.
• 8:23
  SPEAKER_00: How much of the pressure drop could cataract surgery explain?
• 8:26
  SPEAKER_00: This is the study's biggest interpretive problem.
• 8:29
  SPEAKER_00: Alispan was not tested against cataract surgery alone or against ordinary calloplasty.
• 8:35
  SPEAKER_00: Cataract removal can lower pressure on its own, especially when the pressure before surgery is high.
• 8:42
  SPEAKER_00: In the randomized horizon trial, patients with open angle glaucoma had a medication washout baseline mean pressure of about 24.5.
• 8:51
  SPEAKER_00: At 24 months, the cataract surgery only group had an average pressure decrease of 5.3, about 22% of baseline.
• 8:59
  SPEAKER_00: In an ocular hypertension treatment study analysis, cataract surgery was associated with a pressure decrease from a higher baseline, but the effect differed according to baseline pressure and medication use.
• 9:11
  SPEAKER_00: Horizon Trial Report, Ocular Hypertension Treatment Study, Cataract Analysis, Analysis of cataract surgery in treated patients.
• 9:20
  SPEAKER_00: The ALOSPAN announcement implies an overall decrease of about 8.3 from 22.4 to about 14.1.
• 9:27
  SPEAKER_00: As a rough comparison, if the 22.4 baseline was measured after medication washout, cataract-only results in a similar pressure range suggest cataract surgery might explain around 5 mm of mercury or about 22 percentage points of the reported reduction.
• 9:44
  SPEAKER_00: If baseline was measured while patients were using their usual drops, the cataract-only contribution might be closer to 1 to 2 mm of mercury in some comparable treated populations.
• 9:56
  SPEAKER_00: On that basis, a rough estimate is that cataract surgery could explain about 1 to 5 mm of mercury of the 8.3 decrease, roughly 12% to 60% of the absolute reported drop.
• 10:09
  SPEAKER_00: This is a cross-study estimate, not a finding from the AliceBan cohort.
• 10:13
  SPEAKER_00: If the medication protocol and starting pressure were comparable to horizon, the combined glaucoma procedure may have contributed roughly another 3 mm of mercury beyond cataract surgery.
• 10:25
  SPEAKER_00: But that would be the effect of caniloplasty plus reinforcement together, not the effect of the graft by itself.
• 10:32
  SPEAKER_00: The incremental effect of the alospan graft versus ordinary caniloplasty remains unknown.
• 10:38
  SPEAKER_00: A cautious hypothesis might be that the graft adds anywhere from no measurable benefit to roughly 1 to 2 mm of mercury or improved durability.
• 10:48
  SPEAKER_00: A larger effect is possible, but is not demonstrated.
• 10:52
  SPEAKER_00: The 52i results cannot distinguish these possibilities.
• 10:56
  SPEAKER_00: How alospan compares with other glaucoma procedures.
• 10:59
  SPEAKER_00: The studies below involve different glaucoma severities, pressure measurement methods, medication rules, and amounts of cataract surgery.
• 11:07
  SPEAKER_00: Their results are not head-to-head comparisons.
• 11:10
  SPEAKER_00: In particular, some report pressure after medication washout, while others report pressure while patients continue drops.
• 11:18
  SPEAKER_00: For the full table, please open this article on VisualFieldtest.com.
• 11:22
  SPEAKER_00: No directly comparable data are available for whether ALOSPAN reaches 15 or 12 or lower.
• 11:29
  SPEAKER_00: Nor can the six-month 90% result at 18 or lower be compared fairly with five-year outcomes from randomized trials.
• 11:36
  SPEAKER_00: These different time points and medication conditions matter.
• 11:40
  SPEAKER_00: The table also shows that a mean near 14 is not unique to bioreinforcement.
• 11:45
  SPEAKER_00: Conventional canniloplasty, omni, trabeculotomy, and other procedures have produced similar pressures in some study populations.
• 11:53
  SPEAKER_00: The question is whether alospan can achieve better durability or fewer medications in comparable patients.
• 12:00
  SPEAKER_00: What is known and unknown about the donor tissue?
• 12:04
  SPEAKER_00: The boost registry describes allospan's implant as minimally manipulated, homologous use scleral allograph tissue placed within the canal wall region.
• 12:13
  SPEAKER_00: The public study record does not specify its length, exact dimensions, processing steps, cellularity, or whether the tissue is expected to degrade.
• 12:22
  SPEAKER_00: Boost study record.
• 12:23
  SPEAKER_00: Published details about alloflow, Yantrex's separate allograft product for the uvioscleral pathway, should not be silently applied to allo span.
• 12:32
  SPEAKER_00: Alloflow has been described as processed acellular donor sclera with a 5mm length and 500 micrometer width.
• 12:40
  SPEAKER_00: In published cyclodialysis studies, authors reported no implant migration or rejection in their observed follow-up.
• 12:47
  SPEAKER_00: That provides some relevant experience with related donor tissue, but it is not proof that the allo span material has the same dimensions, processing, behavior, or long-term safety.
• 12:58
  SPEAKER_00: Alloflow one-year study published alloflow tissue and technique details.
• 13:03
  SPEAKER_00: What might happen over time?
• 13:05
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 13:10
  SPEAKER_00: A donor scaffold might remain mechanically supportive or become incorporated into surrounding tissue.
• 13:16
  SPEAKER_00: But biological does not mean incapable of scarring.
• 13:20
  SPEAKER_00: Fibrous healing could theoretically narrow the canal or interfere with collector channel openings.
• 13:25
  SPEAKER_00: Conversely, a well-tolerated scaffold might support a more stable channel.
• 13:30
  SPEAKER_00: Human imaging and long-term follow-up are needed to determine what actually happens.
• 13:34
  SPEAKER_00: The published Alloflow experience is encouraging for short-term compatibility, but the location and function are different from an implant in Schlem's Canal.
• 13:43
  SPEAKER_00: Review of Scleral Allografts in Eye Surgery, Alloflow Clinical Series.
• 13:48
  SPEAKER_00: How low can pressure realistically go by keeping Schlem's canal open?
• 13:53
  SPEAKER_00: Opening the natural drainage pathway does not bypass every downstream obstacle.
• 13:59
  SPEAKER_00: Fluid still has to travel through collector channels and into the venous system.
• 14:04
  SPEAKER_00: Pressure in the veins around the eye, episcleral venous pressure, is itself around 7 to 8 mm of mercury in a healthy eye, and there is additional resistance between Schlem's canal and those veins.
• 14:16
  SPEAKER_00: Review of Outflow Physiology.
• 14:18
  SPEAKER_00: That means keeping the canal wide should not be expected to produce the same pressures as an operation that routes fluid outside the natural drainage system.
• 14:28
  SPEAKER_00: A realistic average for a canal-based procedure is more likely in the low to mid-teens than in the single digits.
• 14:35
  SPEAKER_00: Some individuals may reach 10 to 12.
• 14:39
  SPEAKER_00: A durable average below 10 would be biologically less plausible without bypassing more of the natural outflow resistance.
• 14:46
  SPEAKER_00: Trabeculectomy can reach lower pressures, but with a different risk and follow-up burden.
• 14:52
  SPEAKER_00: This is an inference from physiology and results of related procedures, not an allo span-specific measured floor.
• 14:59
  SPEAKER_00: Could allo span and Eantrex cyclodialysis procedure eventually be combined?
• 15:04
  SPEAKER_00: Eantrex alloflow procedure targets a different route, the uvioscleral pathway.
• 15:09
  SPEAKER_00: It creates a controlled opening between the ciliary body and sclera, then uses donor scleral tissue to support that opening.
• 15:17
  SPEAKER_00: Published studies have reported pressure and medication reductions after bioreinforced cyclodialysis, but these are observational clinical series, not randomized comparisons, proving that the allograft itself caused the improvement.
• 15:30
  SPEAKER_00: One-year cyclodialysis results, two-year cyclodialysis results.
• 15:35
  SPEAKER_00: In principle, improving both conventional drainage through Schlem's canal and uveoscleral drainage could increase the total capacity for fluid to leave the eye.
• 15:45
  SPEAKER_00: The roots could work in parallel, but the combined strategy is untested.
• 15:49
  SPEAKER_00: It may add benefit or it may add risks, such as excessive pressure lowering, inflammation, or closure of the cyclodialysis opening.
• 15:58
  SPEAKER_00: The potential is mechanistic speculation, not established human evidence.
• 16:02
  SPEAKER_00: Evidence level and best current estimates, established human evidence.
• 16:07
  SPEAKER_00: The company announced six-month results in 52 eyes, a 37.2% mean pressure reduction from 22.4, 90% at 18 or lower, and a 49.1% reduction in medication use.
• 16:20
  SPEAKER_00: The study combined caniloplasty with cataract surgery and was observational and single-center.
• 16:25
  SPEAKER_00: The exact six-month mean pressure is not separately reported.
• 16:29
  SPEAKER_00: Arithmetic from the rounded numbers implies about 14.1.
• 16:33
  SPEAKER_00: No serious eye-related adverse events or secondary pressure lowering operations were reported through six months.
• 16:40
  SPEAKER_00: Conventional caniloplasty and other Schlem's canal procedures have their own multi-year human data.
• 16:46
  SPEAKER_00: Alospan does not yet have comparable follow-up.
• 16:49
  SPEAKER_00: Strong inference.
• 16:50
  SPEAKER_00: Cataract surgery likely contributed to some of the reported pressure decrease.
• 16:55
  SPEAKER_00: Canaloplasty itself may explain more of the result than the graft.
• 16:59
  SPEAKER_00: The study cannot separate their effects.
• 17:02
  SPEAKER_00: Downstream drainage resistance means a wider canal alone may not reliably deliver very low pressures.
• 17:09
  SPEAKER_00: The 52i results are promising enough to justify a controlled trial, but not enough to establish superior durability.
• 17:16
  SPEAKER_00: Informed speculation.
• 17:18
  SPEAKER_00: These are my estimates, not published trial probabilities.
• 17:22
  SPEAKER_00: Chance the average pressure reduction remains at least 30% at 12 months, about 60%, with a wide plausible range of 40 to 75%.
• 17:31
  SPEAKER_00: Chance that reduction remains at least 30% at 3 years, about 35%, with a plausible range of 15 to 55%, most likely mean pressure in a larger comparable study, approximately 15 to 16 millimeters of mercury.
• 17:46
  SPEAKER_00: A broader population or different medication rules could produce a higher or lower result.
• 17:51
  SPEAKER_00: Chance the biological reinforcement adds a clinically meaningful benefit over ordinary canniloplasty, about 25% with substantial uncertainty.
• 18:00
  SPEAKER_00: By meaningful, I mean a lasting difference, such as around 1.5 millimeters of mercury, or a clear reduction in medication or repeat surgery.
• 18:10
  SPEAKER_00: Chance allo span becomes a mainstream glaucoma procedure, approximately 20% over the next several years, assuming mainstream means broad routine use rather than availability at select sites.
• 18:23
  SPEAKER_00: Randomized evidence and several years of safety follow-up could raise or lower that estimate.
• 18:28
  SPEAKER_00: These forecasts are deliberately cautious.
• 18:31
  SPEAKER_00: The reported pressure result is impressive, but the available evidence does not yet show whether it came from cataract surgery, canalplasty, the graft, or a combination.
• 18:42
  SPEAKER_00: Does reinforcing the eye's natural drainage canal solve one of MiGs's biggest problems?
• 18:47
  SPEAKER_00: It might address one possible weakness of canaloplasty, but that weakness has not yet been shown to be the main reason canaloplasty loses effectiveness.
• 18:56
  SPEAKER_00: The biological rationale is credible.
• 18:59
  SPEAKER_00: Widen the drainage canal and support it without a synthetic implant.
• 19:03
  SPEAKER_00: But canaloplasty already has evidence of multi-year benefit, and the 52i allo span study has not shown that its graft adds to that benefit.
• 19:13
  SPEAKER_00: The trial that would settle the central question is a multi-center randomized study comparing the same canaloplasty technique with versus without the donor allograft.
• 19:23
  SPEAKER_00: If patients need cataract surgery, it should be performed in both groups.
• 19:27
  SPEAKER_00: Medication washout and pressure measurement should be standardized.
• 19:31
  SPEAKER_00: Investigators should follow participants for at least three years, report pressure at 18, 15, and 12 or lower, medication use, repeat surgery, adverse events, and canal dimensions using imaging.
• 19:45
  SPEAKER_00: A five-year extension would be important for testing the durability claim.
• 19:49
  SPEAKER_00: A consistent advantage in the graft group, especially at 2 to 5 years, without more complications, would support the idea that biological reinforcement improves canniloplasty.
• 20:01
  SPEAKER_00: Similar outcomes in both groups would suggest that dilation and cataract surgery explain most of the benefit.
• 20:07
  SPEAKER_00: Current judgment, the six-month results are a promising first signal, not proof that reinforcement makes pressure lowering more durable.
• 20:16
  SPEAKER_00: Until a randomized comparison demonstrates an added benefit, AloSpan should be regarded as an investigational approach with a plausible mechanism and an unresolved central claim.
• 20:27
  SPEAKER_00: All links to sources are available in the text version of this article.
• 20:31
  SPEAKER_00: You can find the full article at VisualFieldTest.com.
• 20:35
  SPEAKER_00: Thanks for listening.
• 20:36
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit VisualFieldTest.com.